Novel Tumor-Specific Antigens for Immunotherapy Identified From Multi-omics Profiling in Thymic Carcinomas

Abstract excerpt

Thymic carcinoma (TC) is the most aggressive thymic epithelial neoplasm. TC patients with microsatellite instability, whole-genome doubling, or alternative tumor-specific antigens from gene fusion are most likely to benefit from immunotherapies. However, due to the rarity of this disease, how to prioritize the putative biomarkers and what constitutes an optimal treatment regimen remains largely unknown....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Monoclonal and Polyclonal Antibodies Research
• Share to Myasthenia Gravis and Thymoma
• Share to vaccines and immunoinformatics approaches